Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abraxane Maintenance in Squamous Cell NSCLC
NCT02027428Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Feb 2014
- Primary completion
- Sep 2017
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of nab-paclitaxel in squamous cell carcinoma of the lung (SCCL) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Progression-Free Survival From Randomization Into Maintenance up to 27.6 months. Started Feb 2014; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT02027428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02027428.